Paul S. Mischel

Paul S. Mischel

Auto-generated profile, based on publicly available information

Paul S. Mischel

Department of Pathology, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2017 in Nature
Verified
Journal Article
Open access
PDF file
KTKristen M. Turner
Kristen M. Turner
VDViraj Deshpande
Viraj Deshpande
DBDoruk Beyter
Doruk Beyter
TKTomoyuki Koga
Tomoyuki Koga
JRJessica Rusert
Jessica Rusert
PMPaul S. Mischel
Paul S. Mischel
Circular extrachromosomal DNA is found in nearly half of human cancers of a wide variety of histologic types, increasing the copy number of driver oncogenes and intratumoral heterogeneity more effectively than chromosomal amplification and contributing to tumor evolution. Extrachromosomal DNA has been shown to play a role in oncogenesis, but its frequency and importance have not been clear. Here, the authors perform whole-genome sequencing, structural modelling and cytogenetic analysis of 17 different types of cancer to explore how extrachromosomal elements contribute to the heterogeneity and plasticity of tumours. They find extrachromosomal DNA in nearly half of the cancers, but in almost no healthy cells, with driver oncogenes being the most commonly amplified, resulting in increased transcript levels. Mathematical modelling predicts that amplification of extrachromosomal DNA could increase oncogene copy number more than chromosomal amplification. The results suggest that extrachromosomal DNA has a broad role in the adaptation and evolution of cancer cells. Human cells have twenty-three pairs of chromosomes. In cancer, however, genes can be amplified in chromosomes or in circular extrachromosomal DNA (ecDNA), although the frequency and functional importance of ecDNA are not understood1,2,3,4. We performed whole-genome sequencing, structural modelling and cytogenetic analyses of 17 different cancer types, including analysis of the structure and function of chromosomes during metaphase of 2,572 dividing cells, and developed a software package called ECdetect to conduct unbiased, integrated ecDNA detection and analysis. Here we show that ecDNA was found in nearly half of human cancers; its frequency varied by tumour type, but it was almost never found in normal cells. Driver oncogenes were amplified most commonly in ecDNA, thereby increasing transcript level. Mathematical modelling predicted that ecDNA amplification would increase oncogene copy number and intratumoural heterogeneity more effectively than chromosomal amplification. We validated these predictions by quantitative analyses of cancer samples. The results presented here suggest that ecDNA contributes to accelerated evolution in cancer.

3 January 2014 in Science
Verified
Journal Article
Closed access
PDF file
DNDavid A. Nathanson
David A. Nathanson
BGBeatrice Gini
Beatrice Gini
JMJack Mottahedeh
Jack Mottahedeh
KVKoppany Visnyei
Koppany Visnyei
TKTomoyuki Koga
Tomoyuki Koga
PMPaul S. Mischel
Paul S. Mischel
Playing Hide and Seek: Targeted cancer therapies have shown promising results in patients, but few of these drugs provide long-term benefits because tumor cells rapidly develop drug resistance. Nathanson et al. (p. 72 , published online 5 December) show that glioblastoma cells can become resistant to erlotinib, an epidermal growth factor receptor (EGFR)–targeted drug, by eliminating extrachromosomal copies of the mutant EGFR gene. After a period of drug withdrawal, the mutant EGFR gene reappears on extrachromosomal DNA and the tumor cells become resensitized. The discovery that cancer cells can evade drug therapy by this “hide and seek” mechanism may help to optimize the dosing schedule of erlotinib in glioblastoma patients.

20 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
SWSihan Wu
Sihan Wu
KTKristen M. Turner
Kristen M. Turner
NNNam Nguyen
Nam Nguyen
RRRamya Raviram
Ramya Raviram
MEMarcella Erb
Marcella Erb
PMPaul S. Mischel
Paul S. Mischel

14 November 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SHSteve Horvath
Steve Horvath
BZB. Zhang
B. Zhang
MCM. Carlson
M. Carlson
KLK. V. Lu
K. V. Lu
SZS. Zhu
S. Zhu
PMP. S. Mischel
P. S. Mischel
Glioblastoma is the most common primary malignant brain tumor of adults and one of the most lethal of all cancers. Patients with this disease have a median survival of 15 months from the time of diagnosis despite surgery, radiation, and chemotherapy. New treatment approaches are needed. Recent works suggest that glioblastoma patients may benefit from molecularly targeted therapies. Here, we address the compelling need for identification of new molecular targets. Leveraging global gene expression data from two independent sets of clinical tumor samples ( n = 55 and n = 65), we identify a gene coexpression module in glioblastoma that is also present in breast cancer and significantly overlaps with the “metasignature” for undifferentiated cancer. Studies in an isogenic model system demonstrate that this module is downstream of the mutant epidermal growth factor receptor, EGFRvIII, and that it can be inhibited by the epidermal growth factor receptor tyrosine kinase inhibitor Erlotinib. We identify ASPM (abnormal spindle-like microcephaly associated) as a key gene within this module and demonstrate its overexpression in glioblastoma relative to normal brain (or body tissues). Finally, we show that ASPM inhibition by siRNA-mediated knockdown inhibits tumor cell proliferation and neural stem cell proliferation, supporting ASPM as a potential molecular target in glioblastoma. Our weighted gene coexpression network analysis provides a blueprint for leveraging genomic data to identify key control networks and molecular targets for glioblastoma, and the principle eluted from our work can be applied to other cancers.

17 August 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HKHoon Kim
Hoon Kim
NNNam-Phuong Nguyen
Nam-Phuong Nguyen
KTKristen Turner
Kristen Turner
SWSihan Wu
Sihan Wu
AGAmit D. Gujar
Amit D. Gujar
RVRoel G. W. Verhaak
Roel G. W. Verhaak

24 January 2014 in Annual Review of Pathology: Mechanisms of Disease
Verified
Journal Article
Closed access
TCTimothy F. Cloughesy
Timothy F. Cloughesy
WCWebster K. Cavenee
Webster K. Cavenee
PMPaul S. Mischel
Paul S. Mischel
Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses are defining the molecular architecture of GBM, uncovering relevant subsets of patients whose disease may require different treatments. Many pharmacological targets have been revealed, promising to transform patient care through targeted therapies. However, for most patients, clinical responses to targeted inhibitors are either not apparent or not durable. In this review, we address the challenge of developing more effective, molecularly guided approaches for the treatment of GBM patients. We summarize the current state of knowledge regarding molecular classifiers and examine their benefit for stratifying patients for treatment. We survey the molecular landscape of the disease, discussing the challenges raised by acquired drug resistance. Furthermore, we analyze the biochemical features of GBM, suggesting a next generation of drug targets, and we examine the contribution of tumor heterogeneity and its implications. We conclude with an analysis of the experimental approaches and their potential benefit to patients.